Long-term results of 131I-tositumomab therapy for non-Hodgkin's lymphoma
Author Information
Author(s): Buchegger F, Antonescu C, Delaloye A Bischof, Helg C, Kovacsovics T, Kosinski M, Mach J-P, Ketterer N
Primary Institution: University Hospital of Lausanne
Hypothesis
Does 131I-tositumomab therapy provide long-term responses in patients with relapsed or refractory indolent non-Hodgkin's lymphoma?
Conclusion
131I-tositumomab RIT demonstrated durable responses, especially in patients who achieved a complete response.
Supporting Evidence
- The overall response rate was 81% in the 16 patients treated.
- Median progression-free survival of the 16 patients was 22.5 months.
- Six of eight complete responders are ongoing after 46–70 months.
Takeaway
This study shows that a special treatment can help people with a type of cancer called non-Hodgkin's lymphoma feel better for a long time.
Methodology
This was a single arm, open-label phase II study evaluating the response rate to 131I-tositumomab in patients with relapsed indolent or transformed B-cell lymphoma.
Potential Biases
Potential bias due to the open-label design and the lack of a control group.
Limitations
The small sample size and the low number of patients with transformed disease limit the generalizability of the findings.
Participant Demographics
{"age":{"median":52.3,"range":"31-77"},"sex":{"male":8,"female":10},"lymphoma_histology":{"follicular":10,"small_lymphocytic":1,"malt":1,"transformed":6}}
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website